Antioxidants vitamin e and 1-aminobenzotriazole prevent experimental non-alcoholic steatohepatitis in mice

Scandinavian Journal of Gastroenterology

Volumn 44, Issue 9, 2009, Pages 1121-1131

  Nan, Yue Min ^a   Wu, Wen Juan ^a   Fu, Na ^a   Liang, Bao Li ^a   Wang, Rong Qi ^a   Li, Liang Xiao ^a   Zhao, Su Xian ^a   Zhao, Jing Min ^b   Yu, Jun ^a,c  

^a HEBEI MEDICAL UNIVERSITY   (China)

^b BEIJING 302 HOSPITAL   (China)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Antioxidant; Apoptosis; Non alcoholic steatohepatitis; Oxidative stress

Indexed keywords

1 AMINOBENZOTRIAZOLE; ADIPONECTIN; ALANINE AMINOTRANSFERASE; ALPHA TOCOPHEROL; ASPARTATE AMINOTRANSFERASE; CHOLINE; CYCLOOXYGENASE 2; GELATINASE A; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPID PEROXIDE; MESSENGER RNA; METHIONINE; PROTEIN BAX; PROTEIN BCL 2; SUPEROXIDE DISMUTASE; TRANSFORMING GROWTH FACTOR BETA1;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; ENZYME ACTIVITY; GENE EXPRESSION REGULATION; GENE REPRESSION; INFLAMMATORY INFILTRATE; LIVER INJURY; LIVER PROTECTION; MALE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; NUTRITIONAL DEFICIENCY; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; UPREGULATION; WESTERN BLOTTING;

ALANINE TRANSAMINASE; ANALYSIS OF VARIANCE; ANIMALS; ANTIOXIDANTS; APOPTOSIS; ASPARTATE AMINOTRANSFERASES; BCL-2-ASSOCIATED X PROTEIN; BLOTTING, WESTERN; CYCLOOXYGENASE 2; FATTY LIVER; GENES, BCL-2; INFLAMMATION; LIPID PEROXIDATION; MALE; MATRIX METALLOPROTEINASE 2; MICE; MICE, INBRED C57BL; NF-KAPPA B P50 SUBUNIT; OXIDATIVE STRESS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSFORMING GROWTH FACTOR BETA1; TRIAZOLES; VITAMIN E;

EID: 70350627681     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.1080/00365520903114912     Document Type: Article

References (45)

1. Paschos P, Paletas K. Non-alcoholic fatty liver disease and metabolic syndrome. Hippokratia 2009;/13:/9-19.
2. Raszeja-Wyszomirska J, Lawniczak M, Marlicz W, Miezyn ́ska-Kurtycz J, Milkiewicz P. Non-alcoholic fatty liver disease: new view. Pol Merkur Lekarski 2008;/24:/568-71.
3. Day C, Saksena S. Non-alcoholic steatohepatitis: definitions and pathogenesis. J Gastroenterol Hepatol 2002;/17 Suppl 3:/ S377-84.
4. Day CP, James OF. Steatohepatitis: A tale of two ''hits''? Gastroenterology 1998;/114:/842-5.
5. Choudhury J, Sanyal AJ. Insulin resistance and the pathogenesis of nonalcoholic fatty liver disease. Clin Liver Dis 2004;8:575-94, ix. (Pubitemid 39141144)
6. Machado M, Cortez-Pinto H. Non-alcoholic steatohepatitis and metabolic syndrome. Curr Opin Clin Nutr Metab Care 2006;/9:/637-42.
7. Mitsuyoshi H, Itoh Y, Okanoue T. Role of oxidative stress in non-alcoholic steatohepatitis. Nippon Rinsho 2006;/64:/ 1077-82.
8. Kojima H, Sakurai S, Uemura M, Fukui H, Morimoto H, Tamagawa Y. Mitochondrial abnormality and oxidative stress in nonalcoholic steatohepatitis. Alcohol Clin Exp Res 2007;/31 suppl 1:/S61-6.
9. Nan YM, Wu WJ, Yao XX, Wang L. The role of apoptosis and the related genes in non-alcoholic steatohepatitis. Zhonghua Ganzangbing Zazhi 2007;/15:/41-6.
10. Farrell GC, Larter CZ, Hou JY, Zhang RH, Yeh MM, Williams J, et al. Apoptosis in experimental NASH is associated with p53 activation and TRAIL receptor expression. J Gastroenterol Hepatol 2009;/24:/443-52.
11. Feldstein AE, Canbay A, Angulo P, Taniai M, Burgart LJ, Lindor KD, et al. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 2003;/125:/437-43.
12. Bugianesi E, Gentilcore E, Manini R, Natale S, Vanni E, Villanova N, et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am. J. Gastroenterol 2005;/100:/ 1082-90.
13. BeştaşA, Kahramanoglu M, Erhan OL, Bolat E, Ozercan I, Gü rsu F, et al. The role of the antioxidants lycopene and vitamin E in the prevention of halothane-induced hepatotoxicity. Methods Find Exp Clin Pharmacol 2008;/30:/ 627-31.
14. Huang H, Chen Y, Ye J. Inhibition of hepatitis C virus replication by peroxidation of arachidonate and restoration by vitamin E. Proc Natl Acad Sci USA 2007;/104:/18666-70.
15. Nishiya T, Kato M, Suzuki T, Maru C, Kataoka H, Hattori C, et al. Involvement of cytochrome P450-mediated metabolism in tienilic acid hepatotoxicity in rats. Toxicol Lett 2008;/183:/81-9.
16. Crincoli CM, Patel NN, Tchao R, Harvison PJ. Role of biotransformation in 3-(3, 5-dichlorophenyl)-2, 4-thiazolidinedione- induced hepatotoxicity in Fischer 344 rats. Toxicology 2008;/250:/100-8.
17. Yu J, Ip E, Dela Peña A, Hou JY, Sesha J, Pera N, et al. COX-2 induction in mice with experimental nutritional steatohepatitis: Role as pro-inflammatory mediator. Hepatology 2006;/43:/826-36.
18. Paschos P, Paletas K. Non-alcoholic fatty liver disease and metabolic syndrome. Hippokratia 2009;/13:/9-19.
19. Chalasani NP, Sanyal AJ, Kowdley KV, Robuck PR, Hoofnagle J, Kleiner DE, et al. Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design. Contemp Clin Trials 2009;/30:/88-96.
20. Roberts EA, Yap J. Nonalcoholic fatty liver disease (NAFLD): Approach in the adolescent patient. Curr Treat Options Gastroenterol 2006;/9:/423-31.
21. Di Sario A, Candelaresi C, Omenetti A, Benedetti A. Vitamin E in chronic liver diseases and liver fibrosis. Vitam Horm 2007;/76:/551-73.
22. Machado MV, Ravasco P, Jesus L, Marques-Vidal P, Oliveira CR, Proença T, et al. Blood oxidative stress markers in nonalcoholic steatohepatitis and how it correlates with diet. Scand J Gastroenterol 2008;/43:/95-102.
23. Mitsuyoshi H, Itoh Y, Okanoue T. Role of oxidative stress in non-alcoholic steatohepatitis. Nippon Rinsho 2006;/64:/ 1077-82.
24. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: From steatosis to cirrhosis. Hepatology 2006;/43:/S99-112.
25. Arvaniti VA, Thomopoulos KC, Tsamandas A, Makri M, Psyrogiannis A, Vafiadis G, et al. Serum adiponectin levels in different types of non alcoholic liver disease. Correlation with steatosis, necroinflammation and fibrosis. Acta Gastroenterol Belg 2008;/71:/355-60.
26. Bugianesi E, Pagotto U, Manini R, Vanni E, Gastaldelli A, De Iasio R, et al. Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to disease severity. J Clin Endocrinol Metab 2005;/90:/3498-504.
27. Kaser S, Moschen A, Cayon A, Kaser A, Crespo J, Pons- Romero F, et al. Adiponectin and its receptors in nonalcoholic steatohepatitis. Gut 2005;/54:/117-21. (Pubitemid 40007229)
28. Dela Pena A, Leclercq I, Field J, George J, Jones B, Farrell G. NF-kB activation, rather than TNF, mediates hepatic inflammation in a murine dietary model of steatohepatitis. Gastroenterology 2005;/129:/1663-74.
29. Jou J, Choi SS, Diehl AM. Mechanisms of disease progression in nonalcoholic fatty liver disease. Semin Liver Dis 2008;/28:/370-9.
30. Nagasawa T, Inada Y, Nakano S, Tamura T, Takahashi T, Maruyama K, et al. Effects of bezafibrate, PPAR panagonist, and GW501516, PPARdelta-agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet. Eur J Pharmacol 2006;/536:/182-91.
31. Brunt EM. Nonalcoholic steatohepatitis. Semin Liver Dis 2004;/24:/3-20.
32. Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology 2004;/40:/46-54.
33. Copaci I, Micu L, Voiculescu M. The role of cytokines in non-alcoholic steatohepatitis [review]. J Gastrointest Liver Dis 2006;/15:/363-73.
34. Shek FW, Benyon RC. How can transforming growth factor beta be targeted usefully to combat liver fibrosis? Eur J Gastroenterol Hepatol6 2004;/16:/123-6.
35. Gouville AC, Boullay V, Krysa G, Pilot J, Brusq JM, Loriolle F, et al. Inhibition of TGF-b signaling by an ALK5 Inhibitor protects rats from dimethylnitrosamine-induced liver fibrosis. Br J Pharmacol 2005;/145:/166-77.
36. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005;/ 115:/209-18.
37. Lotersztajn S, Julien B, Teixeira-Clerc F, Grenard P, Mallat A. Hepatic fibrosis: molecular mechanisms and drug targets. Ann Rev Pharmacol Toxicol 2005;/45:/605-28.
38. Ribeiro PS, Cortez-Pinto H, Sola S, Castro RE, Ramalho RM, Baptista A, et al. Hepatocyte apoptosis, expression of death receptors, and activation of NF-kappaB in the liver of nonalcoholic and alcoholic steatohepatitis patients. Am J Gastroenterol 2004;/99:/1708-17.
39. Malhi H, Gores GJ. Cellular and molecular mechanisms of liver injury. Gastroenterology 2008;/134:/1641-54.
40. Guicciardi ME, Gores GJ. Cheating death in the liver. Nat Med 2004;/10:/587-8.
41. Ramalho RM, Cortez-Pinto H, Castro RE, Solá S, Costa A, Moura MC, et al. Apoptosis and Bcl-2 expression in the livers of patients with steatohepatitis. Eur J Gastroenterol Hepatol 2006;/18:/21-9.
42. Nan YM, Hu YL, Fu N, Wu WJ. Novel effect of the expression of proapoptotic proteins Bad, Bax and Bid in non-alcoholic steatohepatitis. Shijie Huaren Xiaohua Zazhi 2008;/16:/81-5.
43. Antonsson B. Mitochondria and the Bcl-2 family proteins in apoptosis signaling pathways. Mol Cell Biochem 2004;/256- 257:/141-55.
44. Hasegawa T, Yoneda M, Nakamura K, Makino I, Terano A. Plasma transforming growth factor-beta 1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: A pilot study. Aliment Pharmacol Ther 2001;/15:/ 1667-72.
45. Lavine JE. Vitamin E treatment of nonalcoholic steatohepatitis in children: A pilot study. J Pediatr 2000;/136:/734-8.